We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassay Assessed for Diagnosis of Norovirus Gastroenteritis

By LabMedica International staff writers
Posted on 14 Mar 2012
Print article
The sensitivity and specificity of a commercial Norovirus immunochromatographic test has been evaluated on human stool samples.

The immunochromatographic test is based on reverse transcription-polymerase chain reaction (RT-PCR) and the sensitive RT-nested PCR and was compared with another commercial real-time RT-PCR for detection of Norovirus in stool samples.

Scientists at Mahidol University (Bangkok, Thailand) tested 86 stool samples for noroviruses using the commercial immunochromatographic test RIDA QUICK Norovirus, which uses the biotin-streptavidin-peroxidase method. In addition, 54 Norovirus-positive samples from a second test group were also detected, and the copy number of Norovirus quantified by using a commercial real-time RT-PCR. Norovirus GI and GII antigens in stool samples can be detected using the RIDA QUICK Norovirus Test.

The sensitivity was analyzed using stool samples of the two test groups, which were confirmed for Norovirus infection by RT-PCR and RT-nested PCR, respectively. Based on the RT-PCR, the sensitivity of the RIDAQUICK Norovirus assay (R-Biopharm; Darmstadt, Germany) was 83.3% (15/18 samples), but compared with the RT-nested PCR, the sensitivity decreased to 48.2% (26/54 samples). The specificity of the assay was analyzed using Norovirus-negative stool samples from the control group and accounted for 87.5% (28/32 samples). The assay revealed false positives of 12.5%.

Among 23 stool samples showing Norovirus positive by both the RIDA QUICK Norovirus assay and the real-time RT-PCR (Shanghai ZJ Bio-Tech, Shanghai, China), the virus could be detected in samples taken on days 1–8 after onset of illness and these samples harbored Norovirus GII. The real-time RT-PCR for the simultaneous detection of Norovirus GI and GII and quantitation was completed on the LightCycler 1.5 Instrument Real Time PCR System (Roche Diagnostics, Mannheim, Germany). Viral ribonucleic acid (RNA) was extracted using the QIAam Viral RNA extraction kit (QIAGEN GmbH, Hilden, Germany).

The authors concluded that the RIDA QUICK Norovirus assay is rapid and simple to perform. The assay has high sensitivity and specificity. This method is appropriate to use for early diagnosis of acute gastroenteritis caused by noroviruses and for rapid screening of Norovirus infections in patients with acute gastroenteritis in both developed and developing countries where the RT-PCR method has not been established for routine diagnosis. However, negative results where Norovirus is strongly suspected should be further tested by more sensitive molecular techniques.

The study was published online on February 23, 2012, in the European Journal of Clinical Microbiology & Infectious Diseases.

Related Links:
Mahidol University
R-Biopharm
Roche Diagnostics



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.